Cell Regeneration

Cell Regeneration is a fully open-access journal on stem cells and regenerative biology, published by Springer Nature through its SpringerOpen platform for the Chinese Society for Cell Biology, launched in 2012, with a 2025 Journal Impact Factor of 5.6.《细胞再生（英文）》是干细胞与再生生物学领域的完全开放获取期刊，由（Springer Nature）通过（SpringerOpen）平台代表中国细胞生物学学会出版，2012 年创刊，2025 年期刊影响因子为 5.6。

Scope

• The journal aims to provide a worldwide platform for research on stem cells and regenerative biology, developing basic science and fostering its clinical translation in medicine.刊物宗旨是为干细胞与再生生物学研究提供全球性平台，推动基础科学发展并促进其在医学中的临床转化。
• Its declared interests run from embryonic stem cells and induced pluripotent stem cells to tissue-specific stem cells.征稿范围自胚胎干细胞与诱导多能干细胞，延伸到各类组织特异性干细胞。
• Tissue or organ regeneration is a core topic, alongside methodology papers reporting new tools and technologies.组织或器官再生是核心方向之一，报道新工具与新技术的方法学文章亦受欢迎。
• Biomaterials and regeneration, including scaffold design and cell-material interactions, sit inside the scope.生物材料与再生，包括支架设计与细胞—材料相互作用，属于收录范围。
• Clinical translation and application in medicine is an explicit category, reflecting the sponsor's push from bench to bedside.临床转化与医学应用被单列为一类，体现主办方对从实验室走向临床的推动。
• Novel discoveries, theories, methods, technologies and products in stem cell and regenerative research are all welcomed.干细胞与再生研究中的新发现、新理论、新方法、新技术与新产品均在欢迎之列。
• Recent collections have gathered work on single-cell technologies, skeletal muscle regeneration and aging, and organoid models.近期专辑汇集了单细胞技术、骨骼肌再生与衰老以及类器官模型等方向的工作。

History

• Volume 1 appeared in December 2012 under BioMed Central in London, with early support from the Guangzhou Institutes of Biomedicine and Health of the Chinese Academy of Sciences.第 1 卷于 2012 年 12 月由伦敦（BioMed Central）出版，早期曾获中国科学院广州生物医药与健康研究院支持。
• From 2017 to 2019 publishing moved to KeAi Communications in Beijing, and the journal has been the official journal of the Chinese Society for Cell Biology since 2019.2017 至 2019 年间改由北京（KeAi Communications）出版，2019 年起成为中国细胞生物学学会官方期刊。
• Since 2020 Springer has published the title in cooperation with the society, moving it onto the Springer Nature Link platform.2020 年起改由（Springer）与该学会合作出版，刊物迁移至（Springer Nature Link）平台。
• It is an online-only title with electronic ISSN 2045-9769 and uses continuous article publishing rather than fixed issues.本刊为纯在线刊物，电子 ISSN 为 2045-9769，采用连续出版方式而非固定期号。
• Publication costs were fully sponsored by the Chinese Society for Cell Biology in 2025, and since 1 January 2026 authors pay an article processing charge of GBP 1,955, USD 2,680 or EUR 2,260, with waivers available through society sponsorship.2025 年出版费用曾由中国细胞生物学学会全额资助；自 2026 年 1 月 1 日起作者需支付文章处理费，标准为 1,955 英镑、2,680 美元或 2,260 欧元，经学会赞助可获减免。
• The 2025 Journal Impact Factor is 5.6, up from 4.7 in 2024, and the journal ranks Q1 in Cell and Tissue Engineering and Q2 in Cell Biology in ESCI.2025 年期刊影响因子为 5.6，高于 2024 年的 4.7；在（ESCI）中位列细胞与组织工程 Q1、细胞生物学 Q2。

Editors

• Ye-Guang Chen of Tsinghua University serves as editor-in-chief.主编为清华大学陈晔光。
• Four vice editors-in-chief back him up, namely Shaorong Gao of Tongji University, Jinsong Li of the Center for Excellence in Molecular Cell Science, Duanqing Pei of the Guangzhou Institutes of Biomedicine and Health, and Jing-Wei Xiong of Peking University.四位副主编分别为同济大学高绍荣、分子细胞科学卓越创新中心李劲松、广州生物医药与健康研究院裴端卿与北京大学熊敬维。
• The board lists 79 members drawn from China, the United States, Germany, Japan, South Korea, Singapore, Australia, France and the United Kingdom.编委会名录共列 79 位成员，来自中国、美国、德国、日本、韩国、新加坡、澳大利亚、法国与英国。
• Overseas members include Juan Carlos Izpisua Belmonte of the Salk Institute, Kenneth Poss of Duke University, Didier Stainier, Ralf Jauch and Jonathan Slack.海外成员包括（Salk Institute）的（Juan Carlos Izpisua Belmonte）、杜克大学的（Kenneth Poss），以及（Didier Stainier）、（Ralf Jauch）与（Jonathan Slack）等。
• The journal also runs an Early-Career Board for researchers within ten years of completing a PhD.刊物还设有青年编委会，面向博士毕业不超过十年的研究者。
• Review is single anonymized, and official metrics report a median of four days from submission to first decision and 92.5 days to acceptance.评审采用单匿名方式；官方指标显示投稿至首次决定中位数为 4 天，投稿至接受为 92.5 天。